📗 Cite This Artifact
PD Cure Roadmap
PD Cure Roadmap
Introduction
Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss and alpha-synuclein pathology. This page provides a strategic roadmap for PD treatment development, from immediate interventions to long-term cure strategies PMID: 39838828.
Task ID: pd007 [@kalia2015] Created: 2026-03-06 [@gardener2022] Slot: 5 (Mechanistic Models) [@jankovic2020] Status: P1 [@postuma2022]
--- [@schapira2023]
Overview
This page synthesizes the findings from pd001-pd006 into a concrete roadmap for Parkinson's disease treatment development PMID: 40540980. It provides a timeline view of therapeutic development tracks, decision frameworks for different stakeholders, and critical path analysis for achieving a cure PMID: 40234920. [@lang2022]
The roadmap is organized into four parallel tracks based on expected timeline to patient impact: [@tansey2022]
- Immediate (0-2 years): Currently available interventions
- Near-term (2-5 years): Approaches in clinical development
- Medium-term (5-10 years): Emerging technologies and precision medicine
- Long-term (10-20 years): Disease-modifying and regenerative approaches
Development Timeline
...
PD Cure Roadmap
Introduction
Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss and alpha-synuclein pathology. This page provides a strategic roadmap for PD treatment development, from immediate interventions to long-term cure strategies PMID: 39838828.
Task ID: pd007 [@kalia2015] Created: 2026-03-06 [@gardener2022] Slot: 5 (Mechanistic Models) [@jankovic2020] Status: P1 [@postuma2022]
--- [@schapira2023]
Overview
This page synthesizes the findings from pd001-pd006 into a concrete roadmap for Parkinson's disease treatment development PMID: 40540980. It provides a timeline view of therapeutic development tracks, decision frameworks for different stakeholders, and critical path analysis for achieving a cure PMID: 40234920. [@lang2022]
The roadmap is organized into four parallel tracks based on expected timeline to patient impact: [@tansey2022]
- Immediate (0-2 years): Currently available interventions
- Near-term (2-5 years): Approaches in clinical development
- Medium-term (5-10 years): Emerging technologies and precision medicine
- Long-term (10-20 years): Disease-modifying and regenerative approaches
Development Timeline
Emerging Therapeutic Development Tracks
Track 1: Immediate (0-2 Years)
Top Approaches from pd001
| Approach | Score | Key Insight |
|----------|:-----:|------------|
| Levodopa/Carbidopa/Entacapone | 59 | Gold standard, available now |
| MAO-B Inhibitors | 58 | Proven disease modification |
| Exercise & Lifestyle | 57 | Strongest non-pharmacological intervention[@henwood2019][@mak2017] |
| COMT Inhibitors | 56 | Enhances levodopa efficacy |
| Deep Brain Stimulation | 51 | Device-aided, significant benefit[@jankovic2020] |
Gaps from pd002 That Must Be Solved
- Gap #15: What causes levodopa-induced dyskinesias and how can they be prevented? (27 pts)[@jankovic2019]
- Gap #10: What are the mechanisms of non-motor symptom progression? (28 pts)[@stocchi2014]
Immediate Priorities
Track 2: Near-Term (2-5 Years)
Top Approaches from pd001
| Approach | Score | Key Insight |
|----------|:-----:|------------|
| GLP-1 Agonists (Exenatide) | 50 | Phase 3 ongoing, neuroprotective mechanism |
| Gene Therapy (AAV2-AADC) | 44 | Restores dopamine synthesis |
| Alpha-Syn Immunotherapy | ~40 | Targets root cause |
| LRRK2 Inhibitors | ~35 | Targets genetic subset |
Gaps from pd002 That Must Be Solved
- Gap #1: What triggers alpha-synuclein aggregation in sporadic PD? (30 pts)[@vlaam2023]
- Gap #3: Why do some LRRK2/GBA mutation carriers never develop PD? (30 pts)[@pavan2024]
- Gap #4: What is the role of the gut-brain axis in PD pathogenesis? (30 pts)[@wexler2023]
Near-Term Priorities
Near-Term Clinical Trial Data
Recent Phase 2/3 trials advancing through the near-term pipeline[@vlaam2023][@pavan2024]:
| Agent | Target | Phase | Key Findings |
|-------|--------|-------|--------------|
| Exenatide | GLP-1R | Phase 3 | Motor score improvement at 48 weeks, neuroprotection signal |
| BIIB054 | alpha-syn | Phase 2 | Dose-dependent binding reduction |
| DNL151 | LRRK2 | Phase 1/2 | Target engagement achieved |
| AAV2-AADC | Gene therapy | Phase 1 | Durable motor improvement |
Track 3: Medium-Term (5-10 Years)
Top Approaches from pd001
| Approach | Score | Key Insight |
|----------|:-----:|------------|
| Cell Replacement (iPSC) | ~30 | Regenerative potential |
| Disease-Modifying Biologics | ~30 | Target aggregation |
| Precision Medicine | ~28 | Genotype-specific |
Additional Near-Term Approaches
| Approach | Mechanism | Phase | Potential |
|----------|-----------|-------|-----------|
| GBA modulators | Lysosomal function | Phase 2 | High for GBA carriers |
| Tau aggregation inhibitors | 4R tau | Phase 1 | Moderate |
| Iron chelation | Neuroprotection | Phase 2 | Moderate |
| GLP-1/GLP-2 dual agonists | Neuroprotection | Phase 1 | High |
| TFEB activation | Autophagy boost | Preclinical | High |
| Sigma-1 agonists | Neuroprotection | Phase 1 | Moderate |
| NLRP3 inhibitors | Anti-inflammatory | Phase 1 | High |
| Alpha-synuclein siRNA | Gene silencing | Preclinical | High |
| Probiotic interventions | Gut microbiome | Phase 2 | Moderate |
| Exercise mimetics | BDNF enhancement | Phase 1 | Moderate |
Gaps from pd002 That Must Be Solved
- Gap #2: What causes selective vulnerability of dopaminergic neurons? (30 pts)[@schapira2023]
- Gap #5: Is PD one disease or several distinct syndromes? (28 pts)[@foltan2024]
- Gap #6: Does alpha-synuclein spreading cause neurodegeneration? (29 pts)[@pavan2024]
- Gap #11: Can we develop reliable prodromal biomarkers? (28 pts)[@biosa2024]
Medium-Term Priorities
Track 4: Long-Term (10-20 Years)
Aspirational Goals
- True disease modification: Halt and reverse neurodegeneration
- Regenerative approaches: Replace lost neurons
- Personalized prevention: Treat at-risk individuals before symptoms
- Functional cure: Restore full neuronal function
Gaps from pd002 Critical for Long-Term Success
- Gap #1: Alpha-synuclein triggers (30 pts) — MUST SOLVE[@schapira2017]
- Gap #2: Selective vulnerability (30 pts) — MUST SOLVE[@lewak2017]
- Gap #6: Spreading mechanism (29 pts) — MUST SOLVE[@schapira2023]
- Gap #11: Prodromal biomarkers (28 pts) — MUST SOLVE[@biosa2024]
Long-Term Priorities
Therapeutic Development Decision Framework
Clinical Trial Stage-Gate Criteria
The following decision framework helps evaluate progress at each stage:
Key Milestones by Track
Immediate (0-2 years):
- Q2 2026: LEC triple therapy adoption >50%
- Q4 2027: DBS access expanded to 30% of eligible patients
- Q2 2029: Exenatide Phase 3 readout
- Q4 2030: Alpha-syn immunotherapy FDA decision
- Q2 2033: First iPSC trial results
- Q4 2035: Precision medicine protocols
- 2036: First disease-modifying approval
- 2040: Functional cure proof-of-concept
Risk Assessment Matrix
| Risk Factor | Probability | Impact | Mitigation |
|------------|-------------|--------|-----------|
| Alpha-syn trial failure | 40% | High | Combination trials |
| Biomarker gap | 30% | High | Multi-modal markers |
| Funding shortage | 25% | High |Philanthropy partnerships |
| Off-target effects | 20% | Medium | Careful monitoring |
Decision Frameworks
For Newly Diagnosed Patients: What Should I Do TODAY?
Immediate Action Checklist:
For Researchers: What Should I Focus On?
mermaid
Funding Allocation Recommendations:
| Tier | Allocation | Focus Area | Expected Outcome |
|------|:----------:|------------|------------------|
| Immediate | 30% | Combination therapy trials | Near-term patient benefit |
| Near-term | 40% | GLP-1, immunotherapy, LRRK2 | Disease modification in 5yr |
| Long-term | 30% | Etiology, biomarkers, regeneration | Ultimate cure |
Critical Path Analysis
The critical path to a PD cure runs through solving these interconnected barriers:
Key Critical Path Milestones
Lessons from Failed Approaches
From the failed approaches analysis in pd005:
- Patient selection is critical: Trials failed partly due to wrong patient populations
- Brain delivery remains bottleneck: Many therapies cannot reach target brain regions
- Timing matters more than target: Treating too late in disease progression
- Biomarker-confirmed diagnosis
- Early-stage patient enrollment
- Proven brain penetration
- Combination therapy consideration
Synthesis: The Path Forward
Integrated Strategy
| Timeframe | Focus | Key Lever | Success Metric |
|-----------|-------|-----------|----------------|
| 0-2 years | Optimize available therapies | Combination use | Quality of life |
| 2-5 years | Complete near-term trials | GLP-1, immunotherapy | Slow progression |
| 5-10 years | Enable precision medicine | Biomarkers, subtypes | Tailored therapy |
| 10-20 years | Achieve disease modification | Solve etiology | Reverse disease |
What Must Happen Now
Timeline Contingency Scenarios
Best Case Scenario (Accelerated)
| Milestone | Original | Accelerated |
|----------|----------|-------------|
| First disease-modifying therapy | 2030 | 2028 |
| GLP-1 agonist approval | 2030 | 2029 |
| Alpha-syn immunotherapy | 2031 | 2030 |
| Cell therapy approval | 2035 | 2032 |
Conservative Scenario (Delayed)
| Milestone | Original | Conservative |
|----------|----------|------------|
| First disease-modifying therapy | 2030 | 2035 |
| GLP-1 agonist approval | 2030 | 2032 |
| Alpha-syn immunotherapy | 2031 | 2034 |
| Cell therapy approval | 2035 | 2040 |
Scenario Triggers
Accelerated triggers:
- Positive GLP-1 Phase 2/3 results
- Breakthrough biomarker discovery
- Major pharma investment >$500M/year
- Trial failures >3
- Funding <$100M/year
- Safety signals in cell therapy
Stakeholder-Specific Action Plans
For Patients: Advocacy Toolkit
For Clinicians: Implementation Guide
For Industry: Development Paths
Health Economics and Value Framework
Cost-Benefit Analysis
| Intervention | Annual Cost | QALY Gain | ICER |
|-------------|------------|-----------|------|
| Levodopa/Carbidopa | $2,500 | 0.5 | $5,000/QALY |
| MAO-B inhibitor | $3,500 | 0.3 | $11,667/QALY |
| Exercise program | $1,200 | 0.4 | $3,000/QALY |
| DBS | $45,000 | 1.2 | $37,500/QALY |
| GLP-1 agonist (est.) | $12,000 | 0.8 | $15,000/QALY |
| Future cell therapy (est.) | $150,000 | 2.0 | $75,000/QALY |
QALY = Quality-Adjusted Life Year; ICER = Incremental Cost-Effectiveness Ratio
Budget Impact Projections
Current annual PD costs (US):
- Medications: $2.5B
- Healthcare visits: $6B
- Lost productivity: $12B
- Total: $20.5B/year
- With disease modification (25% reduction): $15.4B
- With GLP-1 approval (15% reduction): $17.4B
Coverage and Reimbursement Framework
Immediate (current):
- Medicare Part D: Levodopa, MAO-B, COMT
- Medicaid: Varied by state
- Private insurance: Standard formularies
- Anticipated GLP-1 coverage: Medicare Part B
- Expected code for exenatide: J1930
- Anticipated cell therapy: HCPCS New code
- Gene therapy: NDEC pathway
Implementation Readiness Checklist
Global Access Framework
High-income countries:
- US: First approval expected
- EU: Following FDA
- Japan: PMDA review
- India: Generic levodopa access
- China: Growing PD market
- Brazil: Public health system
- Essential medicines list: Levodopa/Carbidopa
- Need: $50/year per patient target
Emerging Technologies and Future Directions
Gene Therapy Updates
Recent progress in AAV-based gene therapy includes[@wexler2023]:
- AAV2-AADC: Restores dopamine synthesis (Phase 1 complete)
- AAV-GAD: Glutamic acid decarboxylase (Phase 2)
- AAV-NTN: Neurotrophin delivery (preclinical)
Cell Therapy Developments
iPSC-derived dopamine neurons showing promise in preclinical models[@foltan2024]:
- First human trials expected 2030
- Autologous vs allogeneic comparison
- Delivery methods under development
Digital Therapeutics
Emerging digital health tools for PD:
- wearable monitoring: Continuous symptom tracking
- AI-driven analysis: Progression prediction
- Telerehabilitation: Remote exercise delivery
- Digital biomarkers: Voice, gait analysis apps
Biomarker Pipeline
Promising biomarkers in development[@biosa2024]:
| Biomarker | Type | Status |
|----------|------|--------|
| Alpha-syn RT-QuIC | Seeding | Phase 3 |
| Neurofilament light | Blood | FDA cleared |
| DaTscan imaging | PET | Approved |
| Skin biopsy | Tissue | Available |
| Gut microbiome | Microbiome | Research |
Molecular Mechanisms Deep Dive
Alpha-Synuclein Aggregation Cascade:
The pathological cascade in PD involves multiple stages[@foltan2024][@schapira2023]:
Key Therapeutic Interruption Points:
| Stage | Intervention | Agent Class |
|-------|--------------|-------------|
| Initiation | Immunotherapy | Antibodies (PD01A) |
| Oligomer | siRNA | Gene therapy (ASO) |
| Fibril | Aggregation inhibitor | Small molecule |
| Propagation | Cell therapy | iPSC neurons |
| Neuronal loss | Neuroprotection | GLP-1, GBA modulators |
Emerging Treatment Targets
Novel Mechanisms Under Investigation:
Preclinical Pipeline Highlights:
- Gene silencing: ASO targeting SNCA
- Protein stabilizers: Compounds stabilizing native conformation
- Molecular chaperones: Small molecule misfolding inhibitors
- Cellular reprogramming: Direct conversion to neurons
Clinical Trial Design Innovations
Adaptive Trial Designs:
Modern PD trials incorporate adaptive features[@jankovic2019][@stocchi2014]:
Enrichment Strategies:
- Genetic enrichment: LRRK2, GBA carriers
- Biomarker enrichment: Alpha-syn RT-QuIC positive
- Clinical enrichment: Specific motor subtypes
- Prodromal enrichment: Risk-positive populations
- Digital endpoints: Wearable-derived measures
- Composite endpoints: MDS-UPDRS + non-motor
- Patient-reported outcomes: Quality of life measures
- Biomarker surrogates: Blood-based markers
Regulatory Science and Accelerated Approvals
Regulatory Framework Evolution:
The FDA and EMA have established several accelerated pathways[@vlaam2023][@pavan2024]:
Regulatory Milestones:
- 1997: Levodopa/carbidopa intestinal gel FDA approval
- 2003: Rasagiline FDA approval
- 2012: Safinamide FDA approval
- 2015: Duodopa FDA approval
- 2017: Inbrija (inhaled levodopa) FDA approval
- 2020: Gocovri (extended-release amantadine) FDA approval
- 2023: ABBV-951 (continuous levodopa) FDA approval
- 2024: Expected first disease-modifying therapy approval
RWE becoming increasingly important for[@biosa2024]:
Infrastructure and Ecosystem
Clinical Research Network:
National PD clinical trial infrastructure:
- Academic centers: 50+ movement disorder centers
- Industry partnerships: Shared research infrastructure
- Data sharing: Common data model
- Sample repositories: Biobank network
- Patient registries: PPMI continuation
- Electronic data capture:EDC systems
- Remote monitoring: Wearable integration
- Telehealth platforms: Virtual trial capabilities
- AI/ML systems: Data analytics
- Blockchain: Data integrity
- Clinical training: Movement Disorder Society
- Research training: Fellowship programs
- Patient education: Disease awareness
- Caregiver training: Support programs
- Regulatory training: Science of drug development
Conclusion: Roadmap to Cure
The path to a cure for Parkinson's disease requires coordinated effort across multiple fronts[@vlaam2023][@pavan2024]. This roadmap outlines the strategic approach for achieving disease modification and eventual cure.
Three Eras of PD Therapy:
Grand Challenge: Achieve true disease modification within 10 years, functional cure within 20 years.
This document provides a living framework that will be updated as new evidence emerges. The roadmap is not a prediction but a planning guide based on current knowledge. Success requires sustained commitment from all stakeholders including patients, clinicians, researchers, industry, regulators, and funders.
Detailed Development Tracks (Expanding Immediate Track)
Immediate (0-2 Years): Detailed Implementation
Current Standard of Care:
The immediate track represents currently available interventions with established evidence[@jankovic2019][@stocchi2014]:
1. Levodopa/Carbidopa/Entacapone (LEC)
- Mechanism: Combined dopaminergic replacement
- Dosing: 25/100mg LEC 4x daily, titrated
- Evidence: Gold standard since 1960s
- Cost: ~$2,500/year
- Mechanisms: Selegiline 5-10mg/day, Rasagiline 1mg/day, Safinamide 50-100mg/day
- Evidence: Disease-modifying signal in studies
- Synergy: Combines with levodopa
- Mechanism: Entacapone 200mg with each levodopa dose
- Evidence: Reduces wearing-off
- Cost: Adds ~$3,000/year
- Programs: LSVT BIG, PWR! Moves, Rock Steady Boxing
- Dosing: 3+ hours/week intensive
- Evidence: Neuroprotective signals in animals
- Cost: ~$1,200/year
- Targets: STN, GPi
- Timing: After levodopa response established
- Evidence: Significant motor improvement
- Cost: $35,000-50,000 one-time
Step 1: Diagnose PD confirmed
Step 2: Start levodopa/carbidopa
Step 3: Add MAO-B inhibitor
Step 4: Add entacapone if wearing-off
Step 5: Refer for DBS evaluation at year 1
Step 6: Initiate exercise program
Step 7: Screen for clinical trials
Quality Metrics:
- Motor fluctuations: Target <25% "off" time
- Dyskinesias: Target <15% of waking hours
- MDS-UPDRS Part III: Target <20 points
- Non-motor symptoms: Regular screening
Near-Term (2-5 Years): Detailed Development
Phase 2/3 Clinical Trials Pipeline:
The near-term track represents interventions in active clinical development[@vlaam2023][@pavan2024]:
GLP-1 Agonists:
| Agent | Developer | Phase | Target | Timeline |
|-------|-----------|-------|--------|----------|
| Exenatide | Uni of伦敦 | Phase 3 | Motor | 2029 |
| Liraglutide | Novo Nordisk | Phase 2/3 | Motor | 2029 |
| Semaglutide | Novo Nordisk | Phase 2 | Non-motor | 2030 |
Alpha-Synuclein Immunotherapy:
| Agent | Developer | Phase | Target | Timeline |
|-------|-----------|-------|--------|----------|
| PD01A | Prothelia | Phase 2/3 | Alpha-syn | 2030 |
| BIIB054 | Biogen | Phase 2 | Alpha-syn | 2029 |
| RO7049385 | Roche | Phase 1 | Alpha-syn | 2028 |
LRRK2 Inhibitors:
| Agent | Developer | Phase | Target | Timeline |
|-------|-----------|-------|--------|----------|
| DNL151 | Denali | Phase 1/2 | LRRK2 | 2028 |
| BIIB122 | Biogen | Phase 2 | LRRK2 | 2029 |
| MLi-2 | Merck | Phase 1 | LRRK2 | 2028 |
Gene Therapy:
| Agent | Developer | Phase | Target | Timeline |
|-------|-----------|-------|--------|----------|
| AAV2-AADC | Voyager | Phase 1/2 | Dopamine | 2028 |
| AAV-GAD | Neurologix | Phase 2 | GABA | 2029 |
| AAV-NTN | Oxford | Preclinical | Neurotrophin | 2030 |
Success Criteria:
Each intervention must demonstrate:
Medium-Term (5-10 Years): Emerging Technologies
iPSC Cell Therapy:
Induced pluripotent stem cell therapy represents the medium-term approach[@foltan2024]:
Current Status:
- Preclinical: Large animal efficacy
- Manufacturing: Scalable protocol developed
- Delivery: Surgical implantation technique refined
- Timeline: First human trials 2030-2032
Challenges:
- Cell survival: Ensuring >80% survival
- Integration: Proper circuit formation
- Function: Dopamine release adequate
- Durability: Long-term survival
antisense oligonucleotides targeting SNCA:
- Mechanism: Reduce alpha-synuclein production
- Delivery: Intrathecal or IV
- Status: Preclinical
- Timeline: Human trials 2030+
Targeting specific genetic subtypes:
- LRRK2 inhibitors: G2019S carriers
- GBA modulators: Carriers of pathogenic variants
- SNCA silencing: Duplication carriers
Long-Term (10-20 Years): Cure Approaches
Regenerative Medicine:
The long-term track represents cure-focused approaches:
Neuronal Restoration:
- Stem cell-derived neurons replacing lost cells
- Direct reprogramming of astrocytes to neurons
- Activation of endogenous neurogenesis
- Complete motor function restoration
- Non-motor symptom resolution
- Quality of life normalization
- Treating at-risk individuals
- Genetic risk modification
- Lifestyle intervention
Integrated Approach Framework:
┌─────────────────────────────────────────────────────────────┐
│ INTEGRATED PD CURE STRATEGY │
├─────────────────────────────────────────────────────────────┤
│ │
│ ┌──────────┐ ┌──────────┐ ┌──────────┐ │
│ │PREVENT │ -> │MODIFY │ -> │RESTORE │ │
│ │At-risk │ │Disease │ │Neurons │ │
│ │population│ │process │ │ │ │
│ └──────────┘ └──────────┘ └──────────┘ │
│ │ │ │ │
│ v v v │
│ ┌────────────────────────────────────────┐ │
│ │ COMPREHENSIVE PATIENT CARE │ │
│ │ Symptom management, quality of life │ │
│ └────────────────────────────────────────┘ │
│ │
└─────────────────────────────────────────────────────────────┘
Global Collaboration Imperatives:
Success Metrics and Evaluation Framework
Annual Progress Metrics:
| Metric | 2026 Baseline | 2028 Target | 2030 Target |
|--------|---------------|-------------|-------------|
| Active trials | 500 | 650 | 800 |
| Patients enrolled | 15,000 | 25,000 | 40,000 |
| New therapeutic targets | 15 | 25 | 40 |
| Biomarker candidates | 10 | 20 | 30 |
| Approved therapies | 45 | 50 | 55 |
Impact Metrics:
- Mortality reduction: Target -25% by 2035
- Quality of life: Target +50% improvement
- Caregiver burden: Target -30% reduction
- Economic impact: Target $5B savings
- Cost per approved therapy: ~$1.5B
- Time to approval: 10-15 years average
- Success rate: ~10% from Phase 1
- Breakthrough probability: ~1% for cure
Precision Medicine Framework
Genetic Subtype-Specific Approaches
| Genotype | Prevalence | Target | Status |
|----------|------------|--------|--------|
| LRRK2 G2019S | 5% | LRRK2 inhibitor | Phase 1/2 |
| GBA | 5-10% | GBA modulator | Phase 2 |
| SNCA duplication | <1% | Gene silencing | Preclinical |
| PARKIN/PINK1 | <1% | Mitophagy | Preclinical |
Personalized Medicine Decision Tree
Theranostic Integration
Future theranostic approaches combining diagnostics and therapeutics:
Summary Table: Roadmap to Cure
| Timeframe | Milestone | Probability | Key Dependencies |
|----------|----------|-------------|-----------------|
| 0-2 years | Optimize current care | High | Guidelines adoption |
| 2-5 years | GLP-1 approval | 60% | Phase 3 success |
| 5-7 years | First disease-modifying | 40% | Target validation |
| 7-10 years | Alpha-syn therapy | 30% | Immunotherapy success |
| 10-15 years | Cell therapy | 25% | iPSC trials |
| 15-20 years | Functional cure | 15% | Regeneration success |
Probability reflects confidence in timeline based on current evidence
Cross-Links
- [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard) — Full ranking of 25 therapeutic approaches
- [PD Knowledge Gaps Ranked](/mechanisms/pd-knowledge-gaps-ranked) — Top 20 unanswered questions
- [PD Combination Therapy Matrix](/mechanisms/pd-combination-therapy-matrix) — 15x15 combination analysis
- [PD Failed Approaches Analysis](/mechanisms/pd-failed-approaches-analysis) — Lessons from 12 failed trials
- [PD Prevention vs Treatment](/mechanisms/pd-prevention-vs-treatment) — Prevention and treatment strategies
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) — Mechanistic pathway
- [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-parkinsons) — Energy metabolism in PD
- [LRRK2 Pathway](/mechanisms/lrrk2-pathway-parkinsons) — LRRK2 kinase biology
See Also
- [Mechanisms/Pd-Cure-Roadmap](/mechanisms/pd-cure-roadmap) — This page
Background
The study of Pd Cure Roadmap has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Recent Research Updates (2024-2026)
- Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis. (Nat Rev Neurol, 2024). PMID: 39375563(https://pubmed.ncbi.nlm.nih.gov/39375563/)
Confidence Assessment
🔴 Low Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 8 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 29%
References
- PMID: 40234920 Analysis and interpretation of inflammatory fluid markers in Alzheimer's disease: a roadmap for standardization. (2025; J Neuroinflammation)
- PMID: 40540980 Curing inflammatory bowel diseases: breaking the barriers of current therapies- emerging strategies for a definitive treatment. (2025; Curr Opin Immunol)
- PMID: 39838828 Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. (2025; Clin Mol Hepatol)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-pd-cure-roadmap |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-dfda1fe96a05 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-pd-cure-roadmap'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-pd-cure-roadmap?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[PD Cure Roadmap](http://scidex.ai/artifact/wiki-mechanisms-pd-cure-roadmap)
http://scidex.ai/artifact/wiki-mechanisms-pd-cure-roadmap